Osteoarthritis Pain-Pipeline Review, H1 2017

Osteoarthritis Pain-Pipeline Review, H1 2017


  • Products Id :- GMDHC9228IDB
  • |
  • Pages: 202
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Osteoarthritis Pain-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Osteoarthritis Pain-Pipeline Review, H1 2017, provides an overview of the Osteoarthritis Pain (Central Nervous System) pipeline landscape.

Osteoarthritis pain is the most common symptom associated with osteoarthritis which causes disruption of the cartilage. This further leads to rubbing of the bones against each other stimulating pain. The predisposing factors are age, joint injury, obesity and heredity. It may be diagnosed by physical examination and MRI and X-ray imaging. The condition may be controlled by weight control, exercise and medication.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Osteoarthritis Pain-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Osteoarthritis Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Osteoarthritis Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Osteoarthritis Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 6, 22, 5, 1, 22 and 3 respectively. Similarly, the Universities portfolio in Phase II and Discovery stages comprises 1 and 1 molecules, respectively.

Osteoarthritis Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Osteoarthritis Pain (Central Nervous System).

The pipeline guide reviews pipeline therapeutics for Osteoarthritis Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Osteoarthritis Pain (Central Nervous System) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Osteoarthritis Pain (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Osteoarthritis Pain (Central Nervous System)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Osteoarthritis Pain (Central Nervous System).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Osteoarthritis Pain (Central Nervous System) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Osteoarthritis Pain-Overview 8

Osteoarthritis Pain-Therapeutics Development 9

Pipeline Overview 9

Pipeline by Companies 10

Pipeline by Universities/Institutes 14

Products under Development by Companies 15

Products under Development by Universities/Institutes 19

Osteoarthritis Pain-Therapeutics Assessment 20

Assessment by Target 20

Assessment by Mechanism of Action 23

Assessment by Route of Administration 26

Assessment by Molecule Type 28

Osteoarthritis Pain-Companies Involved in Therapeutics Development 30

AbbVie Inc 30

Addex Therapeutics Ltd 30

Allergan Plc 31

Ampio Pharmaceuticals Inc 31

Antibe Therapeutics Inc 32

Aralez Pharmaceuticals Inc 32

Arena Pharmaceuticals Inc 33

Array BioPharma Inc 33

Astellas Pharma Inc 34

Axsome Therapeutics Inc 34

BELLUS Health Inc 35

Boehringer Ingelheim GmbH 35

Cara Therapeutics Inc 36

Chromocell Corp 36

Eli Lilly and Company 37

Elite Pharmaceuticals Inc 37

Eupraxia Pharmaceuticals Inc 38

Flexion Therapeutics Inc 38

Genzyme Corp 39

GlaxoSmithKline Plc 39

Grunenthal GmbH 40

Iroko Pharmaceuticals LLC 40

Marina Biotech Inc 41

Medestea Research & Production SpA 41

MedImmune LLC 42

Merck & Co Inc 42

Nuvo Pharmaceuticals Inc 43

Ono Pharmaceutical Co Ltd 43

Pfizer Inc 44

Phosphagenics Ltd 44

ProteoThera Inc 45

pSivida Corp 45

Purdue Pharma LP 46

Regeneron Pharmaceuticals Inc 46

Rottapharm Biotech Srl 47

Shionogi & Co Ltd 47

Symic Biomedical Inc 48

Taiwan Liposome Company Ltd 48

Vertex Pharmaceuticals Inc 49

Zynerba Pharmaceuticals Inc 49

Osteoarthritis Pain-Drug Profiles 50

(amlodipine besylate + celecoxib)-Drug Profile 50

(celecoxib + lisinopril)-Drug Profile 54

(celecoxib + olmesartan)-Drug Profile 55

(lidocaine hydrochloride + tetracaine)-Drug Profile 56

(naltrexone hydrochloride + oxycodone hydrochloride) SR-Drug Profile 58

2-CCPA-Drug Profile 60

AAT-008-Drug Profile 61

ADX-71441-Drug Profile 62

AF-219-Drug Profile 66

Ampion-Drug Profile 70

APD-371-Drug Profile 79

AQU-010-Drug Profile 80

ARRY-954-Drug Profile 81

AS-288640100-Drug Profile 82

ASP-7962-Drug Profile 83

ATB-346-Drug Profile 84

BI-1026706-Drug Profile 89

BLU-5937-Drug Profile 91

cannabidiol-Drug Profile 92

capsaicin-Drug Profile 97

CC-8464-Drug Profile 100

cebranopadol-Drug Profile 102

celecoxib-Drug Profile 105

CR-4056-Drug Profile 106

CRB-0089-Drug Profile 108

dapansutrile-Drug Profile 109

dexamethasone SR-Drug Profile 110

difelikefalin-Drug Profile 111

duloxetine hydrochloride DR-Drug Profile 120

ELS-130-Drug Profile 123

fasinumab-Drug Profile 124

fluticasone propionate ER-Drug Profile 127

grapiprant-Drug Profile 128

GSK-3196165-Drug Profile 130

GZ-389988-Drug Profile 133

ibuprofen-Drug Profile 134

MEDI-7352-Drug Profile 135

naproxen sodium-Drug Profile 136

NEO-6860-Drug Profile 138

OLP-1002-Drug Profile 139

onabotulinumtoxinA-Drug Profile 140

ONO-4474-Drug Profile 145

oxycodone ER-Drug Profile 146

PA-300 DR-Drug Profile 149

PA-65020-Drug Profile 150

PRT-1000-Drug Profile 152

S-120083-Drug Profile 153

SB-061-Drug Profile 154

Small Molecules for Osteoarthritis Pain-Drug Profile 156

Small Molecules to Block Calcium Ion Channel for Osteoarthritis Pain-Drug Profile 157

Small Molecules to Block Nav1.7 for Osteoarthritis Pain-Drug Profile 158

Small Molecules to Inhibit CGRP for Migraine and Osteoarthritis Pain-Drug Profile 159

Small Molecules to Inhibit MMP-13 for Osteoarthritis Pain and Inflammation-Drug Profile 160

Small Molecules to Inhibit PDE2 for Osteoarthritis Pain-Drug Profile 161

tanezumab-Drug Profile 162

TLC-599-Drug Profile 166

triamcinolone acetonide ER-Drug Profile 168

VG-201-Drug Profile 175

VM-902A-Drug Profile 176

VX-150-Drug Profile 177

WITH-1101-Drug Profile 178

zoledronic acid-Drug Profile 179

Osteoarthritis Pain-Dormant Projects 182

Osteoarthritis Pain-Discontinued Products 185

Osteoarthritis Pain-Product Development Milestones 187

Featured News & Press Releases 187

Appendix 197

Methodology 197

Coverage 197

Secondary Research 197

Primary Research 197

Expert Panel Validation 197

Contact Us 197

Disclaimer 198

List of Figures

Number of Products under Development for Osteoarthritis Pain, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

List of Tables

Number of Products under Development for Osteoarthritis Pain, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Osteoarthritis Pain-Pipeline by AbbVie Inc, H1 2017

Osteoarthritis Pain-Pipeline by Addex Therapeutics Ltd, H1 2017

Osteoarthritis Pain-Pipeline by Allergan Plc, H1 2017

Osteoarthritis Pain-Pipeline by Ampio Pharmaceuticals Inc, H1 2017

Osteoarthritis Pain-Pipeline by Antibe Therapeutics Inc, H1 2017

Osteoarthritis Pain-Pipeline by Aralez Pharmaceuticals Inc, H1 2017

Osteoarthritis Pain-Pipeline by Arena Pharmaceuticals Inc, H1 2017

Osteoarthritis Pain-Pipeline by Array BioPharma Inc, H1 2017

Osteoarthritis Pain-Pipeline by Astellas Pharma Inc, H1 2017

Osteoarthritis Pain-Pipeline by Axsome Therapeutics Inc, H1 2017

Osteoarthritis Pain-Pipeline by BELLUS Health Inc, H1 2017

Osteoarthritis Pain-Pipeline by Boehringer Ingelheim GmbH, H1 2017

Osteoarthritis Pain-Pipeline by Cara Therapeutics Inc, H1 2017

Osteoarthritis Pain-Pipeline by Chromocell Corp, H1 2017

Osteoarthritis Pain-Pipeline by Eli Lilly and Company, H1 2017

Osteoarthritis Pain-Pipeline by Elite Pharmaceuticals Inc, H1 2017

Osteoarthritis Pain-Pipeline by Eupraxia Pharmaceuticals Inc, H1 2017

Osteoarthritis Pain-Pipeline by Flexion Therapeutics Inc, H1 2017

Osteoarthritis Pain-Pipeline by Genzyme Corp, H1 2017

Osteoarthritis Pain-Pipeline by GlaxoSmithKline Plc, H1 2017

Osteoarthritis Pain-Pipeline by Grunenthal GmbH, H1 2017

Osteoarthritis Pain-Pipeline by Iroko Pharmaceuticals LLC, H1 2017

Osteoarthritis Pain-Pipeline by Marina Biotech Inc, H1 2017

Osteoarthritis Pain-Pipeline by Medestea Research & Production SpA, H1 2017

Osteoarthritis Pain-Pipeline by MedImmune LLC, H1 2017

Osteoarthritis Pain-Pipeline by Merck & Co Inc, H1 2017

Osteoarthritis Pain-Pipeline by Nuvo Pharmaceuticals Inc, H1 2017

Osteoarthritis Pain-Pipeline by Ono Pharmaceutical Co Ltd, H1 2017

Osteoarthritis Pain-Pipeline by Pfizer Inc, H1 2017

Osteoarthritis Pain-Pipeline by Phosphagenics Ltd, H1 2017

Osteoarthritis Pain-Pipeline by ProteoThera Inc, H1 2017

Osteoarthritis Pain-Pipeline by pSivida Corp, H1 2017

Osteoarthritis Pain-Pipeline by Purdue Pharma LP, H1 2017

Osteoarthritis Pain-Pipeline by Regeneron Pharmaceuticals Inc, H1 2017

Osteoarthritis Pain-Pipeline by Rottapharm Biotech Srl, H1 2017

Osteoarthritis Pain-Pipeline by Shionogi & Co Ltd, H1 2017

Osteoarthritis Pain-Pipeline by Symic Biomedical Inc, H1 2017

Osteoarthritis Pain-Pipeline by Taiwan Liposome Company Ltd, H1 2017

Osteoarthritis Pain-Pipeline by Vertex Pharmaceuticals Inc, H1 2017

Osteoarthritis Pain-Pipeline by Zynerba Pharmaceuticals Inc, H1 2017

Osteoarthritis Pain-Dormant Projects, H1 2017

Osteoarthritis Pain-Dormant Projects, H1 2017 (Contd..1), H1 2017

Osteoarthritis Pain-Dormant Projects, H1 2017 (Contd..2), H1 2017

Osteoarthritis Pain-Discontinued Products, H1 2017

Osteoarthritis Pain-Discontinued Products, H1 2017 (Contd..1), H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

AbbVie Inc, Addex Therapeutics Ltd, Allergan Plc, Ampio Pharmaceuticals Inc, Antibe Therapeutics Inc, Aralez Pharmaceuticals Inc, Arena Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Inc, Axsome Therapeutics Inc, BELLUS Health Inc, Boehringer Ingelheim GmbH, Cara Therapeutics Inc, Chromocell Corp, Eli Lilly and Company, Elite Pharmaceuticals Inc, Eupraxia Pharmaceuticals Inc, Flexion Therapeutics Inc, Genzyme Corp, GlaxoSmithKline Plc, Grunenthal GmbH, Iroko Pharmaceuticals LLC, Marina Biotech Inc, Medestea Research & Production SpA, MedImmune LLC, Merck & Co Inc, Nuvo Pharmaceuticals Inc, Ono Pharmaceutical Co Ltd, Pfizer Inc, Phosphagenics Ltd, ProteoThera Inc, pSivida Corp, Purdue Pharma LP, Regeneron Pharmaceuticals Inc, Rottapharm Biotech Srl, Shionogi & Co Ltd, Symic Biomedical Inc, Taiwan Liposome Company Ltd, Vertex Pharmaceuticals Inc, Zynerba Pharmaceuticals Inc

select a license

Single User License
USD 2000 INR 129140
Site License
USD 4000 INR 258280
Corporate User License
USD 6000 INR 387420

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com